Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Toso

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Journal for Immunotherapy of Cancer|November 17, 2024
Inhibition of Cbl-b restores effector functions of human intratumoral NK cellsSofia Tundo, Marcel Trefny, Andrijana Rodić, et al.
Nature Communications|June 19, 2015
A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumoursMadhuri Kalathur, Alberto Toso, Jingjing Chen, et al.
Science Translational Medicine|June 3, 2026
Claudin-1 targeting suppresses tumor growth, invasion, and metastasis in patient-derived cholangiocarcinoma modelsZeina Nehme, Marion Muller, Jade Brochon, et al.
Journal of Hepatology|October 29, 2022
Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironmentNatascha Roehlen, Marion Muller, Zeina Nehme, et al.
Science Translational Medicine|December 21, 2022
A monoclonal antibody targeting nonjunctional claudin-1 inhibits fibrosis in patient-derived models by modulating cell plasticityNatascha Roehlen, Antonio Saviano, Houssein El Saghire, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Journal for Immunotherapy of Cancer|November 17, 2024
Inhibition of Cbl-b restores effector functions of human intratumoral NK cellsSofia Tundo, Marcel Trefny, Andrijana Rodić, et al.
Nature Communications|June 19, 2015
A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumoursMadhuri Kalathur, Alberto Toso, Jingjing Chen, et al.
Science Translational Medicine|June 3, 2026
Claudin-1 targeting suppresses tumor growth, invasion, and metastasis in patient-derived cholangiocarcinoma modelsZeina Nehme, Marion Muller, Jade Brochon, et al.
Journal of Hepatology|October 29, 2022
Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironmentNatascha Roehlen, Marion Muller, Zeina Nehme, et al.
Science Translational Medicine|December 21, 2022
A monoclonal antibody targeting nonjunctional claudin-1 inhibits fibrosis in patient-derived models by modulating cell plasticityNatascha Roehlen, Antonio Saviano, Houssein El Saghire, et al.
Pageof 4